Ascendis Pharma A/S
ASND
31 hedge funds and large institutions have $416M invested in Ascendis Pharma A/S in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
65.21% more ownership
Funds ownership: 0% → 65.21% (+65%)
48% more capital invested
Capital invested by funds: $281M → $416M (+$135M)
41% more funds holding
Funds holding: 22 → 31 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$34.5M |
| 2 |
DM
Deerfield Management
New York
|
+$21M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.8M |
| 5 |
O
OrbiMed
New York
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.26M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$1.07M |
| 3 |
NC
Nexthera Capital
New York
|
-$923K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$302K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$14.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $106K | +$105K | +5,247 | New |
|
27
Bank of America
Charlotte,
North Carolina
| $88K | +$22K | +1,100 | +34% |
|
28
Morgan Stanley
New York
| $13K | +$13.2K | +662 | New |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $12K | -$4.59K | -230 | -27% |
|
|
30
UBS Group
Zurich,
Switzerland
| $4K | -$14.3K | -718 | -78% |
|
31
US Bancorp
Minneapolis,
Minnesota
| $2K | +$1.52K | +76 | New |
|
|
SCM
32
Sio Capital Management
New York
| – | -$2.26M | -112,497 | Closed |
|
|
CS
33
Credit Suisse
Zurich,
Switzerland
| – | -$302K | -15,031 | Closed |
|
ASND Hedge Fund Activity: Q4 2016 in Review
31 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2016, worth a combined $416M — up 48% from $281M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ASND positions and 2 closed out — a net gain of 9 holders — while 13 added to existing stakes and 4 trimmed.
The largest buyer was RA Capital Management, adding an estimated $34.5M. The largest seller was Sio Capital Management, exiting entirely with an estimated $2.26M sold.
- 31 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2016, up from 22 in Q3 2016.
- Funds reported $416M of Ascendis Pharma A/S stock for Q4 2016, up 48% quarter-over-quarter.
- 11 funds opened new Ascendis Pharma A/S positions in Q4 2016 and 2 closed out, a net change of +9 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2016 was RA Capital Management, an estimated $34.5M added.
- The largest Ascendis Pharma A/S seller in Q4 2016 was Sio Capital Management, an estimated $2.26M sold.
Based on aggregated 13F filings for Q4 2016.